AbbVie (NYSE:ABBV) Q2 Adjusted Earnings, Net Revenue Drop

/ / Health Care /

AbbVie (NYSE:ABBV) reported Q2 adjusted earnings  of $2.91 per diluted share, down from $3.37 a year earlier. Analysts polled by Capital IQ expected $2.81. Net revenue for the quarter ended June 30 was $13.87 billion, down from $14.58 billion a year earlier. Analysts surveyed by Capital IQ expected $13.52 billion. The company said it is raising its full-year 2023 adjusted earnings guidance to $10.90 to $11.10 per diluted share from $10.57 to $10.97. Analysts polled by Capital IQ expect adjusted EPS of $10.89.

AbbVie (NYSE:ABBV) Q2 Adjusted Earnings, Net Revenue Drop Read Post »

Honeywell (NASDAQ:HON) Q2 Adjusted Earnings, Sales Increase; Updates 2023 Outlook

/ / Industrials /

Honeywell International (NASDAQ:HON) reported Q2 adjusted earnings  of $2.23 per diluted share, up from $2.10 per share a year earlier. Analysts polled by Capital IQ expected adjusted EPS of $2.21. Net sales for the quarter ended June 30 were $9.15 billion, compared with $8.95 billion a year earlier. Analysts surveyed by Capital IQ expected $9.17 billion. Honeywell also said it now expects 2023 adjusted EPS to be $9.60 to $9.80, compared with the prior outlook of $9.55 to $9.80. Analysts polled by Capital IQ expect adjusted EPS of $9.15. Sales for the year are projected to be $36.7 billion to $37.3 billion, compared with the prior outlook of $36.5 billion to $37.3 billion. Analysts polled by Capital IQ expect $37 billion.

Honeywell (NASDAQ:HON) Q2 Adjusted Earnings, Sales Increase; Updates 2023 Outlook Read Post »

Boston Scientific (NYSE:BSX) Q2 Adjusted Earnings, Sales Rise

/ / Health Care /

Boston Scientific (NYSE:BSX) reported Q2 adjusted earnings  of $0.53 per share, up from $0.44 a year earlier. Analysts polled by Capital IQ expected $0.49. Net sales for the quarter ended June 30 were $3.60 billion, compared with $3.24 billion a year earlier. Analysts surveyed by Capital IQ expected $3.50 billion. For Q3, the medical technology company said it expects adjusted EPS of $0.46 to $0.48. Analysts surveyed by Capital IQ project $0.48. The company expects net sales for the quarter to grow from 8.5% to 10.5% compared with a year earlier. For 2023, the company said it now expects adjusted EPS of $1.96 to $2, from the prior outlook of $1.90 to $1.96 Analysts polled by Capital IQ expect $1.96.The company also raised its net sales growth outlook for the year to an 11% to 12% increase, from its previously announced range of 8.5% to 11%.

Boston Scientific (NYSE:BSX) Q2 Adjusted Earnings, Sales Rise Read Post »

Scroll to Top